{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:19Z","timestamp":1792511899030,"version":"4.5.0"},"reference-count":267,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jconrel.2024.01.063","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T11:58:03Z","timestamp":1707566283000},"page":"708-736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Next generation therapeutics for retinal neurodegenerative diseases"],"prefix":"10.1016","volume":"367","author":[{"given":"Matthew B.","family":"Appell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahnavi","family":"Pejavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Pasupathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Vishnu Kiran","family":"Rompicharla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saed","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiersten","family":"Malmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Kolodziejski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Ensign","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.01.063_bb0005","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41591-022-01862-8","article-title":"Regenerative and restorative medicine for eye disease","volume":"28","author":"Van Gelder","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1167\/iovs.04-0832","article-title":"Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix","volume":"46","author":"Guo","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0015","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/ceo.13834","article-title":"Retinal pigment epithelium and age-related macular degeneration: a review of major disease mechanisms","volume":"48","author":"Somasundaran","year":"2020","journal-title":"Clin. Experiment. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0030","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/genes11101120","article-title":"Mechanisms of photoreceptor death in retinitis Pigmentosa","volume":"11","author":"Newton","year":"2020","journal-title":"Genes."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0035","unstructured":"Ophthalmology FDA Approved Drugs CenterWatch, (n.d.). https:\/\/www.centerwatch.com\/directories\/1067-fda-approved-drugs\/topic\/104-ophthalmology (accessed August 9, 2023)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bjo.74.8.477","article-title":"A study of the causes of non-compliance by patients prescribed eyedrops","volume":"74","author":"Winfield","year":"1990","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.joco.2017.09.002","article-title":"Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India","volume":"30","author":"Rajurkar","year":"2018","journal-title":"J. Curr. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100901","article-title":"Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma","volume":"82","author":"Kompella","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0055","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.3390\/ijms221910594","article-title":"Ocular Therapeutics and molecular delivery strategies for Neovascular age-related macular degeneration (nAMD)","volume":"22","author":"Sarkar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0060","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41433-020-0770-y","article-title":"Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases","volume":"34","author":"Seah","year":"2020","journal-title":"Eye."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/17425247.1.1.99","article-title":"Periocular routes for retinal drug delivery","volume":"1","author":"Raghava","year":"2004","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1871527315666151110124957","article-title":"Rabbit models of ocular diseases: new relevance for classical approaches","volume":"15","author":"Zernii","year":"2016","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0080","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal Ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0085","unstructured":"JoVE Peer Reviewed Scientific Video Journal - Methods and Protocols, (n.d.). https:\/\/app.jove.com\/pdf\/53878\/use-of-rabbit-eyes-in-pharmacokinetic-studies-of-intraocular-drugs (accessed August 9, 2023)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0090","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI123980","article-title":"A nonhuman primate model of inherited retinal disease","volume":"129","author":"Moshiri","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0095","doi-asserted-by":"crossref","first-page":"26280","DOI":"10.1073\/pnas.1902292116","article-title":"The primate model for understanding and restoring vision","volume":"116","author":"Picaud","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jconrel.2022.03.031","article-title":"Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020","volume":"345","author":"Peng","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0105","first-page":"47","article-title":"Ocular drug delivery systems: an overview, world","volume":"2","author":"Patel","year":"2013","journal-title":"Aust. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0110","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/OPTH.S118409","article-title":"Systemic side effects of eye drops: a pharmacokinetic perspective","volume":"10","author":"Farkouh","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.exer.2013.07.027","article-title":"Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins","volume":"117","author":"Hodges","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120924","article-title":"Drug delivery to the anterior segment of the eye: a review of current and future treatment strategies","volume":"607","author":"Mofidfar","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/pharmaceutics11070321","article-title":"Penetration enhancers in ocular drug delivery","volume":"11","author":"Moiseev","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17425247.2022.2017878","article-title":"Topical drug delivery to the retina: obstacles and routes to success","volume":"19","author":"Loftsson","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations","volume":"12","author":"Varela-Fern\u00e1ndez","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0140","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","author":"Li","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0145","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Ghasemi Falavarjani","year":"2013","journal-title":"Eye."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0002-9394(99)00129-4","article-title":"High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection","volume":"128","author":"Weijtens","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0155","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jcrs.2003.12.057","article-title":"Prevention of endophthalmitis","volume":"30","author":"Buzard","year":"2004","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0160","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.3390\/jcm11164717","article-title":"Subretinal injection techniques for retinal disease: a review","volume":"11","author":"Irigoyen","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0165","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000479157","article-title":"Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases","volume":"58","author":"Peng","year":"2017","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0175","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the Back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/895013","article-title":"Critical assessment of implantable drug delivery devices in glaucoma management","volume":"2013","author":"Manickavasagam","year":"2013","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0185","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/pharmaceutics13050701","article-title":"Polymeric implants for the treatment of intraocular eye diseases: trends in biodegradable and non-biodegradable materials","volume":"13","author":"Garc\u00eda-Estrada","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0190","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized Phase 3 trial of the port delivery system with Ranibizumab for Neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0195","first-page":"257","article-title":"Refill-exchange procedure of the port delivery system with Ranibizumab: overview and clinical trial experience, ophthalmic Surg","volume":"53","author":"Khanani","year":"2022","journal-title":"Lasers Imag. Retina."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0200","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0205","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/febs.16330","article-title":"The blood\u2013retina barrier in health and disease","volume":"290","author":"O\u2019Leary","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0210","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/978-1-4614-4711-5_3","article-title":"The blood-retina barrier: tight junctions and barrier modulation","volume":"763","author":"Campbell","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100803","article-title":"Interactions of the choroid, Bruch\u2019s membrane, retinal pigment epithelium, and neurosensory retina collaborate to form the outer blood-retinal-barrier","volume":"76","author":"Fields","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.visres.2017.05.009","article-title":"The inner blood-retinal barrier: cellular basis and development","volume":"139","author":"D\u00edaz-Cor\u00e1nguez","year":"2017","journal-title":"Vis. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0225","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-020-00270-w","article-title":"The role of systemic antimicrobials in the treatment of Endophthalmitis: a review and an international perspective","volume":"9","author":"Grzybowski","year":"2020","journal-title":"Ophthalmol Therapy"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0230","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0733-8635(18)30318-8","article-title":"Ocular effects of topical and systemic steroids","volume":"10","author":"Renfro","year":"1992","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0235","first-page":"866","article-title":"Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives, drug Deliv","volume":"11","author":"Gaballa","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0240","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0245","article-title":"Don't Let Glaucoma Steal Your Sight!","year":"2020","journal-title":"Cent. Dis. Control Prev."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0250","series-title":"Handb. Nutr. Diet Eye","first-page":"29","article-title":"Chapter 4 - Glaucoma: An overview","author":"Sacc\u00e0","year":"2014"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0255","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4103\/0301-4738.41411","article-title":"Current profile of secondary glaucomas","volume":"56","author":"Gadia","year":"2008","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0260","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.328.7431.97","article-title":"Glaucoma\u20141: Diagnosis","volume":"328","author":"Khaw","year":"2004","journal-title":"BMJ."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0265","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/bjophthalmol-2015-307223","article-title":"Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis","volume":"100","author":"Kapetanakis","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0270","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/2008-322X.183914","article-title":"Update on normal tension glaucoma","volume":"11","author":"Mallick","year":"2016","journal-title":"J. Ophthalmic Vis. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/ICU.0b013e3282f3919b","article-title":"Normal-tension glaucoma: is it different from primary open-angle glaucoma?","volume":"19","author":"Shields","year":"2008","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0280","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/0301-4738.133481","article-title":"New directions in the treatment of normal tension glaucoma","volume":"62","author":"Song","year":"2014","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0285","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.matbio.2014.03.007","article-title":"The role of matricellular proteins in glaucoma","volume":"37","author":"Wallace","year":"2014","journal-title":"Matrix Biol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0290","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1080\/14656566.2020.1795130","article-title":"Current and new pharmacotherapeutic approaches for glaucoma","volume":"21","author":"Shalaby","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0295","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2165\/00002512-199202030-00005","article-title":"Ocular \u03b2-blockers in Glaucoma management","volume":"2","author":"Brooks","year":"1992","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0300","series-title":"Betaxolol, in: StatPearls","author":"Tajran","year":"2023"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0305","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ajhp\/62.7.691","article-title":"Glaucoma and its treatment: a review","volume":"62","author":"Lee","year":"2005","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0310","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1001\/archopht.1978.03910060491022","article-title":"Clonidine: effects on aqueous humor formation and intraocular pressure","volume":"96","author":"Macri","year":"1978","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0315","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1517\/14656560903300103","article-title":"Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics","volume":"10","author":"Costagliola","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0320","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2013.0179","article-title":"Effects of prostaglandin analogues on aqueous humor outflow pathways","volume":"30","author":"Winkler","year":"2014","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0325","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1167\/iovs.09-4955","article-title":"Cellular basis for bimatoprost effects on human conventional outflow","volume":"51","author":"Stamer","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0330","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40266-020-00769-8","article-title":"Bimatoprost implant: first approval","volume":"37","author":"Shirley","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0340","first-page":"2001908","article-title":"Drug-Free, nonsurgical reduction of intraocular pressure for four months after Suprachoroidal injection of hyaluronic acid hydrogel","volume":"8","author":"Chae","year":"2021","journal-title":"Adv. Sci. Weinh. Baden-Wurtt. Ger."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2022.213162","article-title":"Suprachoroidal injection of polyzwitterion hydrogel for treating glaucoma","volume":"142","author":"Hao","year":"2022","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0350","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1208\/s12249-017-0710-8","article-title":"PLGA nanoparticles as subconjunctival injection for Management of Glaucoma","volume":"18","author":"Salama","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0355","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1021\/acsami.6b16509","article-title":"Sustained release of Brimonidine from a new composite drug delivery system for treatment of Glaucoma","volume":"9","author":"Sun","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0360","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.carbpol.2016.02.080","article-title":"Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment","volume":"144","author":"Cheng","year":"2016","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0365","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202170034","article-title":"Lollipop-inspired multilayered drug delivery hydrogel for dual effective, long-term, and NIR-defined Glaucoma treatment","volume":"21","author":"Wang","year":"2021","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0370","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2019.05.025","article-title":"Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma","volume":"305","author":"Xu","year":"2019","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0375","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2019.01.012","article-title":"Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma","volume":"297","author":"Arranz-Romera","year":"2019","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0380","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.ophtha.2016.06.038","article-title":"Latanoprost-eluting contact lenses in glaucomatous monkeys","volume":"123","author":"Ciolino","year":"2016","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0385","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s13346-021-00987-6","article-title":"A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells","volume":"12","author":"Kim","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0390","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/pharmaceutics13050647","article-title":"Ion-complex microcrystal formulation provides sustained delivery of a multimodal kinase inhibitor from the subconjunctival space for protection of retinal ganglion cells","volume":"13","author":"Hsueh","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0395","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fbioe.2020.00228","article-title":"Hydrogel biomaterials for application in ocular drug delivery","volume":"8","author":"Lynch","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0400","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41551-020-00606-8","article-title":"Gelling hypotonic polymer solution for extended topical drug delivery to the eye","volume":"4","author":"Kim","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0405","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1038\/s41598-017-09379-8","article-title":"Long term Glaucoma drug delivery using a topically retained gel\/microsphere eye drop","volume":"7","author":"Fedorchak","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0410","first-page":"3085","article-title":"An in situ-forming polyzwitterion hydrogel: towards vitreous substitute application","volume":"6","author":"He","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0415","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s13346-015-0240-4","article-title":"A biodegradable ocular implant for long-term suppression of intraocular pressure","volume":"5","author":"Ng","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0420","author":"ForSight Vision5, Inc"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0425","author":"Elios Vision, Inc"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0430","unstructured":"MediPrint Ophthalmics, Inc., A Phase 2a Study of Safety, Tolerability, and Efficacy of Drug-Delivering Contact Lens LL-BMT1 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension, clinicaltrials.gov, 2022. https:\/\/clinicaltrials.gov\/study\/NCT04747808 (accessed August 9, 2023)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0435","author":"PolyActiva Pty Ltd"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0440","author":"PolyActiva Pty Ltd"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0445","year":"2022","journal-title":"Ophthalmol. Times."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0450","author":"Nicox Ophthalmics, Inc"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0455","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990\u20132010: a systematic analysis","volume":"1","author":"Bourne","year":"2013","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0460","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2022","journal-title":"Genes Dis."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0465","unstructured":"D.L.S. OD, and Paul M. Karpecki, 21st Century AMD Treatments, (n.d.). https:\/\/www.reviewofoptometry.com\/article\/21st-century-amd-treatments (accessed August 10, 2023)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0470","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/bmb\/ldn012","article-title":"Age-related macular degeneration: diagnosis and management","volume":"85","author":"Cook","year":"2008","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0475","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2147\/OPTH.S92359","article-title":"Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects","volume":"9","author":"Danis","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0480","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0485","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0490","first-page":"513","article-title":"The diagnosis and treatment of age-related macular degeneration","volume":"117","author":"Stahl","year":"2020","journal-title":"Dtsch. \u00c4rztebl. Int."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0495","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.4266","article-title":"Mechanisms of age-related macular degeneration and therapeutic opportunities","volume":"232","author":"van Lookeren Campagne","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0500","unstructured":"SYFOVRE\u00ae (Pegcetacoplan Injection), (n.d.). https:\/\/syfovre.com (accessed January 2, 2024)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0505","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0510","author":"Apellis Pharmaceuticals, Inc"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0515","unstructured":"Izervay (Avacincaptad Pegol Intravitreal Solution) CenterWatch, (n.d.). https:\/\/www.centerwatch.com\/directories\/1067-fda-approved-drugs\/listing\/4890-izervay-avacincaptad-pegol-intravitreal-solution (accessed January 2, 2024)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0520","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/JEP.S259298","article-title":"Current and future anti-VEGF agents for neovascular age-related macular degeneration","volume":"13","author":"Kaiser","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0525","author":"Regeneron Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0530","author":"Hoffmann-La Roche"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0535","unstructured":"Genentech: Press Releases Friday, Oct 22, 2021, (n.d.). https:\/\/www.gene.com\/media\/press-releases\/14935\/2021-10-22\/fda-approves-genentechs-susvimo-a-first- (accessed August 10, 2023)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0540","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40123-016-0058-2","article-title":"Strategies for improving patient comfort during intravitreal injections: results from a survey-based study","volume":"5","author":"Gomez","year":"2016","journal-title":"Ophthalmol Therapy"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0545","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1136\/bjophthalmol-2013-303844","article-title":"What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?","volume":"98","author":"Avery","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0550","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17425247.2020.1735348","article-title":"Penetratin-modified lutein nanoemulsion in-situ gel for the treatment of age-related macular degeneration","volume":"17","author":"Ge","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0555","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.4.3.11","article-title":"Topical ocular drug delivery to the back of the eye by mucus-penetrating particles","volume":"4","author":"Schopf","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0560","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/tvst.10.14.23","article-title":"A novel eye drop formulation for potential treatment of neovascular age-related macular degeneration","volume":"10","author":"Huang","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0565","doi-asserted-by":"crossref","first-page":"eaai8030","DOI":"10.1126\/scitranslmed.aai8030","article-title":"Tyrosine kinase blocking collagen IV\u2013derived peptide suppresses ocular neovascularization and vascular leakage","volume":"9","author":"Lima e Silva","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0570","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.carbon.2022.09.045","article-title":"Anti-angiogenic carbon nanovesicles loaded with bevacizumab for the treatment of age-related macular degeneration","volume":"201","author":"Anand","year":"2023","journal-title":"Carbon."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0575","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1080\/10717544.2018.1474967","article-title":"Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization","volume":"25","author":"Mu","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0580","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41467-020-14340-x","article-title":"Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles","volume":"11","author":"Tsujinaka","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0585","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11095-018-2519-x","article-title":"Topical drug delivery to the posterior segment of the eye: addressing the challenge of preclinical to clinical translation","volume":"35","author":"Rodrigues","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0590","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13346-020-00733-4","article-title":"Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD)","volume":"10","author":"Yadav","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0595","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41433-018-0066-7","article-title":"Statins in retinal disease","volume":"32","author":"Al-Janabi","year":"2018","journal-title":"Eye."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0600","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/jbm.a.35446","article-title":"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment","volume":"103","author":"Varshochian","year":"2015","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0605","doi-asserted-by":"crossref","first-page":"13775","DOI":"10.1073\/pnas.0803241105","article-title":"A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells","volume":"105","author":"Karagiannis","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0610","author":"AbbVie"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0615","unstructured":"Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Clearside Biomedical, Inc.- IR Site, (n.d.). https:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/clearside-biomedical-announces-positive-6-month-results-oasis (accessed August 10, 2023)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0620","author":"Clearside Biomedical, Inc"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0625","author":"EyePoint Pharmaceuticals, Inc"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0630","first-page":"869","article-title":"Under the lens: diabetic retinopathy","volume":"8","author":"The Lancet Diabetes & Endocrinology","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0635","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0640","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0645","unstructured":"Diabetes, (n.d.). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes (accessed August 10, 2023)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0650","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0655","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1055\/s-0035-1556731","article-title":"Thrombosis and hemorrhage in diabetic retinopathy: a perspective from an inflammatory standpoint","volume":"41","author":"Murugesan","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0660","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cmet.2012.11.012","article-title":"Vascular complications of diabetes: mechanisms of injury and protective factors","volume":"17","author":"Rask-Madsen","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0665","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/0271678X15610340","article-title":"What is a pericyte?","volume":"36","author":"Attwell","year":"2016","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0670","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.2337\/diabetes.51.10.3107","article-title":"Pericytes and the pathogenesis of diabetic retinopathy","volume":"51","author":"Hammes","year":"2002","journal-title":"Diabetes."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0675","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4093\/dmj.2018.0182","article-title":"Pathophysiology of diabetic retinopathy: the old and the new","volume":"42","author":"Kusuhara","year":"2018","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0680","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1167\/iovs.17-21973","article-title":"Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy","volume":"58","author":"Boss","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0685","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0278-5846(03)00023-X","article-title":"A new view of diabetic retinopathy: a neurodegenerative disease of the eye","volume":"27","author":"Barber","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0690","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.survophthal.2021.08.011","article-title":"Clinical electroretinography in diabetic retinopathy: a review","volume":"67","author":"McAnany","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0695","first-page":"75","article-title":"Diabetic retinopathy","volume":"107","author":"Kollias","year":"2010","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0700","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","article-title":"Diabetic macular edema: evidence-based management","volume":"66","author":"Browning","year":"2018","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0705","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0710","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"B.M.J.P. Group","year":"1998","journal-title":"BMJ."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0715","first-page":"CD011234","article-title":"Laser photocoagulation for proliferative diabetic retinopathy","volume":"2014","author":"Evans","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0720","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal Aflibercept for the treatment of severe nonproliferative diabetic retinopathy","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0730","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"YOSEMITE and RHINE investigators, efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0735","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4103\/0301-4738.36474","article-title":"Bevacizumab: off-label use in ophthalmology","volume":"55","author":"Grisanti","year":"2007","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0740","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.3390\/ijms22073427","article-title":"Involvement of cytokines in the pathogenesis of diabetic macular edema","volume":"22","author":"Noma","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0745","unstructured":"A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema - Full Text View ClinicalTrials.gov, (n.d.). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT00168337 (accessed August 10, 2023)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0750","unstructured":"A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema - Full Text View ClinicalTrials.gov, (n.d.). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT00168389 (accessed August 10, 2023)."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0755","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Ozurdex MEAD study group, three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0760","author":"Alimera Sciences"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0765","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/03007995.2018.1560779","article-title":"Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials","volume":"35","author":"Holden","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0770","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"FAME study group, long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0775","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph0547s70","article-title":"Streptozotocin-induced diabetic models in mice and rats","volume":"70","author":"Furman","year":"2015","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0780","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcell.2017.00055","article-title":"Pancreatic Beta cell identity in humans and the role of type 2 diabetes","volume":"5","author":"Marchetti","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0785","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","article-title":"Animal models of choroidal and retinal neovascularization","volume":"29","author":"Grossniklaus","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04589","article-title":"Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences","volume":"6","author":"Laddha","year":"2020","journal-title":"Heliyon."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0795","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MJT.0b013e3181c08081","article-title":"PPAR-gamma agonists and their role in type 2 diabetes mellitus management","volume":"17","author":"Berm\u00fadez","year":"2010","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121045","article-title":"Simultaneous amelioration of diabetic ocular complications in lens and retinal tissues using a non-invasive drug delivery system","volume":"608","author":"Srinivasarao","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0805","first-page":"321","article-title":"Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years","volume":"21","author":"Islam","year":"2007","journal-title":"Eye Lond. Engl."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0810","first-page":"423","article-title":"The significance of Akt\/NF-\u03bab signaling pathway in the posterior cataract animal model","volume":"118","author":"Shao","year":"2017","journal-title":"Bratisl. Lek. Listy"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0815","first-page":"36","article-title":"Combination therapies in ophthalmology: implications for intravitreal delivery","volume":"6","author":"Peyman","year":"2011","journal-title":"J. Ophthalmic Vis. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0820","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.2147\/IJN.S316564","article-title":"Hyaluronic-coated albumin nanoparticles for the non-invasive delivery of Apatinib in diabetic retinopathy","volume":"16","author":"Radwan","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0825","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ijbiomac.2022.10.168","article-title":"Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: a new dimension to an anticancer drug","volume":"224","author":"Sharma","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0830","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/IJN.S184574","article-title":"Neuroprotective effect of insulin-loaded chitosan nanoparticles\/PLGA-PEG-PLGA hydrogel on diabetic retinopathy in rats","volume":"14","author":"Rong","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.118217","article-title":"Chitosan coated nanoparticles for efficient delivery of bevacizumab in the posterior ocular tissues via subconjunctival administration","volume":"267","author":"Pandit","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0840","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/acs.molpharmaceut.8b01319","article-title":"Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration","volume":"16","author":"Qiu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0845","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s00018-003-2322-6","article-title":"Fenofibrate inhibits angiogenesis in vitro and in vivo","volume":"60","author":"Varet","year":"2003","journal-title":"Cell. Mol. Life Sci. CMLS."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0850","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.actbio.2020.09.015","article-title":"3D printing of drug-loaded multi-shell rods for local delivery of bevacizumab and dexamethasone: a synergetic therapy for retinal vascular diseases","volume":"116","author":"Won","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0855","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nm0206-171","article-title":"Angiogenesis and inflammation face off","volume":"12","author":"Imhof","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0860","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0865","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two Phase III pivotal trials of Brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0870","author":"OcuTerra Therapeutics, Inc"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0875","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3928\/23258160-20220923-02","article-title":"The safety and biological activity of OTT166, a novel topical selective integrin inhibitor for the treatment of diabetic eye disease: a Phase 1b study, ophthalmic Surg","volume":"53","author":"Boyer","year":"2022","journal-title":"Lasers Imaging Retina."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0880","author":"Bayer"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0885","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","article-title":"Discovery of the soluble guanylate cyclase activator Runcaciguat (BAY 1101042)","volume":"64","author":"Hahn","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0890","first-page":"216","article-title":"Role of nitric oxide in retinal cell death","volume":"4","author":"Roth","year":"1997","journal-title":"Clin. Neurosci. N. Y. N."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0895","author":"Oculis"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0900","author":"AsclepiX Therapeutics, Inc"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0905","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/MOP.0000000000000690","article-title":"Retinitis pigmentosa: recent advances and future directions in diagnosis and management","volume":"30","author":"Fahim","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0910","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2017.10.004","article-title":"Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives","volume":"63","author":"Dias","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0915","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrg2717","article-title":"Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait","volume":"11","author":"Wright","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0920","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis pigmentosa","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0925","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.preteyeres.2017.08.004","article-title":"The mechanism of cone cell death in retinitis Pigmentosa","volume":"62","author":"Campochiaro","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0930","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.preteyeres.2015.06.005","article-title":"Pharmacological approaches to retinitis pigmentosa: a laboratory perspective","volume":"48","author":"Guadagni","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0935","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/ars.2015.6327","article-title":"Is there excess oxidative stress and damage in eyes of patients with retinitis Pigmentosa?","volume":"23","author":"Campochiaro","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0940","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.preteyeres.2009.05.003","article-title":"Structure of cone photoreceptors","volume":"28","author":"Mustafi","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0945","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041307","article-title":"Lessons learned from the development of the first FDA-approved gene therapy drug, Voretigene Neparvovec-rzyl","volume":"13","author":"Bennett","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0950","author":"Park"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0955","author":"Johns Hopkins University"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0960","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ophtha.2017.09.019","article-title":"Assessment of the electronic retinal implant alpha AMS in restoring Vision to blind patients with end-stage retinitis Pigmentosa","volume":"125","author":"Edwards","year":"2018","journal-title":"Ophthalmology."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0965","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4103\/tjo.tjo_47_21","article-title":"Gene therapy for retinitis pigmentosa","volume":"11","author":"Piri","year":"2021","journal-title":"Taiwan J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0970","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet Lond. Engl."},{"issue":"110","key":"10.1016\/j.jconrel.2024.01.063_bb0975","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1001\/archopht.1992.01080230134038","article-title":"Morphometric analysis of macular photoreceptors and ganglion cells in retinas with retinitis pigmentosa","volume":"1960","author":"Stone","year":"1992","journal-title":"Arch. Ophthalmol. Chic. Ill"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0980","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nphoton.2012.104","article-title":"Photovoltaic retinal prosthesis with High pixel density","volume":"6","author":"Mathieson","year":"2012","journal-title":"Nat. Photonics"},{"key":"10.1016\/j.jconrel.2024.01.063_bb0985","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jamaophthalmol.2019.1476","article-title":"One-year safety and performance assessment of the Argus II retinal prosthesis: a postapproval study","volume":"137","author":"Schaffrath","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb0990","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.preteyeres.2015.09.003","article-title":"The Argus\u00ae II retinal prosthesis system","volume":"50","author":"Luo","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1000","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cell.2020.04.033","article-title":"Dynamic stimulation of visual cortex produces form Vision in sighted and blind humans","volume":"181","author":"Beauchamp","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1005","first-page":"2479","article-title":"Gene therapy in animal models of autosomal dominant retinitis pigmentosa","volume":"18","author":"Rossmiller","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2013.07.008","article-title":"Encapsulated cell therapy for neurodegenerative diseases: from promise to product","volume":"67\u201368","author":"Emerich","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1015","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1167\/iovs.12-9970","article-title":"Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases","volume":"53","author":"Kauper","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","article-title":"Ciliary neurotrophic factor retinitis Pigmentosa study groups, randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa","volume":"156","author":"Birch","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2015.05.003","article-title":"Cell encapsulation: technical and clinical advances","volume":"36","author":"Orive","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2019.01.032","article-title":"Injectable cell-encapsulating composite alginate-collagen platform with inducible termination switch for safer ocular drug delivery","volume":"201","author":"Wong","year":"2019","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046474","article-title":"The Royal College of surgeons rat: an animal model for inherited retinal degeneration with a still unknown genetic defect","volume":"162","author":"Strauss","year":"1998","journal-title":"Acta Anat. (Basel)"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41565-020-0696-3","article-title":"Subretinally injected semiconducting polymer nanoparticles rescue vision in a rat model of retinal dystrophy","volume":"15","author":"Maya-Vetencourt","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1045","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/mt.2014.181","article-title":"The expression pattern of systemically injected AAV9 in the developing mouse retina is determined by age","volume":"23","author":"Byrne","year":"2015","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1050","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-vision-102016-061413","article-title":"Vectors and gene delivery to the retina","volume":"3","author":"Planul","year":"2017","journal-title":"Annu. Rev. Vis. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/genes10040287","article-title":"Adeno-associated viral vectors as a tool for large gene delivery to the retina","volume":"10","author":"Trapani","year":"2019","journal-title":"Genes."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1065","first-page":"3","article-title":"Ocular immune privilege, F1000 Biol","volume":"2","author":"Zhou","year":"2010","journal-title":"Rep."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors - implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1075","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.omtm.2022.01.011","article-title":"Systemic and local immune responses to intraocular AAV vector administration in non-human primates","volume":"24","author":"Ail","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1080","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3390\/pharmaceutics14091973","article-title":"Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy","volume":"14","author":"Ren","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1085","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/brv.12718","article-title":"Humoral immune responses to AAV gene therapy in the ocular compartment","volume":"96","author":"Whitehead","year":"2021","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1090","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1095","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1100","doi-asserted-by":"crossref","first-page":"14716","DOI":"10.1038\/ncomms14716","article-title":"Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice","volume":"8","author":"Yu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/hum.2018.193","article-title":"Somatic gene editing of GUCY2D by AAV-CRISPR\/Cas9 alters retinal structure and function in mouse and macaque","volume":"30","author":"McCullough","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fcell.2018.00053","article-title":"In vivo applications of CRISPR-based genome editing in the retina","volume":"6","author":"Yu","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1125","doi-asserted-by":"crossref","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1130","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.omtn.2022.10.011","article-title":"The future of non-viral gene delivery for the treatment of inherited retinal diseases","volume":"30","author":"Sharma","year":"2022","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ymthe.2019.11.031","article-title":"Rhodopsin genomic loci DNA nanoparticles improve expression and rescue of retinal degeneration in a model for retinitis Pigmentosa","volume":"28","author":"Zheng","year":"2020","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1140","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2020.1804853","article-title":"Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases","volume":"29","author":"Xue","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1145","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/bph.12330","article-title":"Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy","volume":"170","author":"Guzman-Aranguez","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1150","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1155","doi-asserted-by":"crossref","first-page":"18476","DOI":"10.1073\/pnas.1112758108","article-title":"Long-term RNA interference gene therapy in a dominant retinitis pigmentosa mouse model","volume":"108","author":"Jiang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1160","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2021.02.026","article-title":"Co-encapsulation of Cas9 mRNA and guide RNA in polyplex micelles enables genome editing in mouse brain","volume":"332","author":"Abbasi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1165","doi-asserted-by":"crossref","first-page":"eadd4623","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2019.06.042","article-title":"Non-viral delivery of chemically modified mRNA to the retina: subretinal versus intravitreal administration","volume":"307","author":"Devoldere","year":"2019","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1175","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/02713683.2019.1565890","article-title":"Morphology and composition of the inner limiting membrane: species-specific variations and relevance toward drug delivery research","volume":"44","author":"Peynshaert","year":"2019","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1180","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4103\/1673-5374.306063","article-title":"The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery","volume":"16","author":"Ross","year":"2021","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1185","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/hum.2020.023","article-title":"Evaluation of photoreceptor transduction efficacy of capsid-modified adeno-associated viral vectors following intravitreal and subretinal delivery in sheep","volume":"31","author":"Ross","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1190","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ajo.2022.03.014","article-title":"Intravitreal Administration of Stanniocalcin-1 rescues photoreceptor degeneration with reduced oxidative stress and inflammation in a porcine model of retinitis Pigmentosa","volume":"239","author":"Rosa","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1195","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4142\/jvs.2014.15.4.475","article-title":"Stanniocalcin-1 protects bovine intestinal epithelial cells from oxidative stress-induced damage","volume":"15","author":"Wu","year":"2014","journal-title":"J. Vet. Sci."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1200","doi-asserted-by":"crossref","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1205","author":"GenSight Biologics"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1210","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2147\/IJN.S157000","article-title":"DNA nanoparticles are safe and nontoxic in non-human primate eyes","volume":"13","author":"Kelley","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1215","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/pharmaceutics12030198","article-title":"Niosome-based approach for in situ gene delivery to retina and brain cortex as immune-privileged tissues","volume":"12","author":"Al Qtaish","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1220","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2013.11.004","article-title":"A novel cationic niosome formulation for gene delivery to the retina","volume":"174","author":"Puras","year":"2014","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1225","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/jphp.12940","article-title":"Hyaluronic acid-modified cationic niosomes for ocular gene delivery: improving transfection efficiency in retinal pigment epithelium","volume":"70","author":"Qin","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijpharm.2016.02.043","article-title":"The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells","volume":"503","author":"Ojeda","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1235","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0169-328X(00)00035-8","article-title":"Upregulation of CD44 expression in the retina during the rds degeneration","volume":"77","author":"Krishnamoorthy","year":"2000","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1240","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jconrel.2019.05.010","article-title":"Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes","volume":"304","author":"Mashal","year":"2019","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jconrel.2008.12.015","article-title":"Cellular uptake of self-assembled cationic peptide-DNA complexes: multifunctional role of the enhancer chloroquine","volume":"135","author":"Yang","year":"2009","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1250","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ymthe.2021.04.024","article-title":"Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations","volume":"29","author":"Dulla","year":"2021","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1255","author":"ProQR Therapeutics"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1260","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1471-4159.2010.07092.x","article-title":"Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration","volume":"116","author":"Oveson","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177998","article-title":"Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats","volume":"12","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1270","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1098-1004(2001)17:1<42::AID-HUMU5>3.0.CO;2-K","article-title":"Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies","volume":"17","author":"Sohocki","year":"2001","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1275","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jconrel.2021.09.039","article-title":"Retinal neuroprotection by controlled release of a VCP inhibitor from self-assembled nanoparticles","volume":"339","author":"Sen","year":"2021","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1280","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1285","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and subretinal injections of AAV using Transscleral microneedles for retinal gene delivery in nonhuman Primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1290","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host immune responses after Suprachoroidal delivery of AAV8 in nonhuman primate eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1295","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1172\/JCI77507","article-title":"Schlemm\u2019s canal: more than meets the eye, lymphatics in disguise","volume":"124","author":"Karpinich","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2024.01.063_bb1300","author":"NightstaRx Ltd"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1305","author":"MeiraGTx UK II Ltd"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1310","author":"4D Molecular Therapeutics"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1315","author":"STZ eyetrial"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1325","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1330","author":"ProQR Therapeutics"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1335","author":"MeiraGTx UK II Ltd"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1340","author":"Editas Medicine, Inc"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1345","author":"Ocugen"},{"key":"10.1016\/j.jconrel.2024.01.063_bb1350","author":"SparingVision"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:57:52Z","timestamp":1759165072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":267,"alternative-id":["S0168365924000786"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.063","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next generation therapeutics for retinal neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}